American HealthCare Capital is pleased to introduce an ACHC accredited, Home Infusion and Closed-Door Specialty Pharmacy for sale that is licensed in 34 states and has multiple locations. The company is in the final stage of URAC 3.0 accreditation and has been in business for over 40 years (acquired by current ownership in 2012) with consistent growth year-over-year. One of the contributing factors of this growth is an industry-wide shift from hospital infusions to outpatient infusion settings.
Their drug therapies include IVIG and other specialty, rare disease state medications. Recently, they gained access to a limited distribution medication with the potential for more LD specialty drugs. They are fully capable of Compounding under USP guidelines, which they have not focused on to date.
In 2017, the company generated $19.4 Million in revenue with adjusted EBITDA of $2.5 Million. In 2018, they are projected to reach $25 Million in revenue with an adjusted EBITDA of approximately $4 Million.
There is a full complement of staff including a Pharmacist in Charge, Technicians, and a Director of Nursing who coordinates the nursing staff for infusion administrations. All staff, including senior management, are expected to remain with the company after the sale.
The asking price for this opportunity is $25 Million plus inventory.
